ENXTPA:GNRO

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Market Cap

€75.8m

Last Updated

2021/06/21 23:41 UTC

Data Sources

Company Financials +

Executive Summary

GeNeuro SA, a clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases. More Details


Snowflake Analysis

Adequate balance sheet with weak fundamentals.

Share Price & News

How has GeNeuro's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: GNRO is more volatile than 90% of French stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: GNRO's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of French stocks.


Market Performance


7 Day Return

-0.3%

GNRO

-2.3%

FR Biotechs

-0.2%

FR Market


1 Year Return

22.9%

GNRO

28.7%

FR Biotechs

34.2%

FR Market

Return vs Industry: GNRO underperformed the French Biotechs industry which returned 28% over the past year.

Return vs Market: GNRO underperformed the French Market which returned 36.2% over the past year.


Shareholder returns

GNROIndustryMarket
7 Day-0.3%-2.3%-0.2%
30 Day-7.5%0.3%3.6%
90 Day-3.9%-7.5%11.0%
1 Year22.9%22.9%28.7%28.7%38.3%34.2%
3 Year-43.3%-43.3%-15.1%-15.1%34.3%23.2%
5 Year-57.6%-57.6%-41.2%-41.3%94.0%65.9%

Long-Term Price Volatility Vs. Market

How volatile is GeNeuro's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is GeNeuro undervalued compared to its fair value and its price relative to the market?

13.72x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate GNRO's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate GNRO's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: GNRO is unprofitable, so we can't compare its PE Ratio to the European Biotechs industry average.

PE vs Market: GNRO is unprofitable, so we can't compare its PE Ratio to the French market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate GNRO's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: GNRO is overvalued based on its PB Ratio (13.9x) compared to the FR Biotechs industry average (4.2x).


Future Growth

How is GeNeuro forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

-18.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: GNRO is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: GNRO is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: GNRO is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if GNRO's revenue is forecast to grow faster than the French market.

High Growth Revenue: Insufficient data to determine if GNRO's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if GNRO's Return on Equity is forecast to be high in 3 years time


Past Performance

How has GeNeuro performed over the past 5 years?

1.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: GNRO is currently unprofitable.

Growing Profit Margin: GNRO is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: GNRO is unprofitable, but has reduced losses over the past 5 years at a rate of 1.3% per year.

Accelerating Growth: Unable to compare GNRO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: GNRO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (21.8%).


Return on Equity

High ROE: GNRO has a negative Return on Equity (-162.52%), as it is currently unprofitable.


Financial Health

How is GeNeuro's financial position?


Financial Position Analysis

Short Term Liabilities: GNRO's short term assets (€7.7M) exceed its short term liabilities (€2.3M).

Long Term Liabilities: GNRO's short term assets (€7.7M) exceed its long term liabilities (€2.7M).


Debt to Equity History and Analysis

Debt Level: GNRO's debt to equity ratio (3.2%) is considered satisfactory.

Reducing Debt: GNRO's debt to equity ratio has reduced from 7.9% to 3.2% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: GNRO has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if GNRO has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Dividend

What is GeNeuro current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate GNRO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate GNRO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if GNRO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if GNRO's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of GNRO's dividend in 3 years as they are not forecast to pay a notable one for the French market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.3yrs

Average management tenure


CEO

Jesus Martin-Garcia (59 yo)

5.42yrs

Tenure

€735,000

Compensation

Mr. Jesús Martin-Garcia is the Founding Partner, General Partner, and Director of Eclosion SA. He serves at GeNeuro SA as the Chairman of the Board since February 06, 2006 and Chief Executive Officer since...


CEO Compensation Analysis

Compensation vs Market: Jesus's total compensation ($USD871.37K) is above average for companies of similar size in the French market ($USD268.35K).

Compensation vs Earnings: Jesus's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: GNRO's management team is considered experienced (3.3 years average tenure).


Board Members

Experienced Board: GNRO's board of directors are considered experienced (5.9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

GeNeuro SA's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: GeNeuro SA
  • Ticker: GNRO
  • Exchange: ENXTPA
  • Founded: 2006
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €75.754m
  • Shares outstanding: 20.47m
  • Website: https://www.geneuro.ch

Number of Employees


Location

  • GeNeuro SA
  • 3 chemin du Pré-Fleuri
  • Plan-les-Ouates
  • Geneva
  • 1228
  • Switzerland

Listings


Biography

GeNeuro SA, a clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases. The company’s lead therapeutic candidate is temelimab, a monoclonal an...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/06/21 23:41
End of Day Share Price2021/06/21 00:00
Earnings2020/12/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.